STAT6 and acute lymphoblastic leukemia: In particular, we have demonstrated that STAT6 and PDAP1, via a putative STAT6–ERK–NF-κB network, may represent useful molecular targets for treatment-resistant ALL, particularly in the absence of clinically available IGF1/R inhibitors.